DE60033814T2 - Monoklonaler Antikörper der Faktor VIII selbst in molarem Überschuß nur teilweise inaktiviert und eine Methode zur Herstellung solch eines Antikörpers - Google Patents

Monoklonaler Antikörper der Faktor VIII selbst in molarem Überschuß nur teilweise inaktiviert und eine Methode zur Herstellung solch eines Antikörpers Download PDF

Info

Publication number
DE60033814T2
DE60033814T2 DE60033814T DE60033814T DE60033814T2 DE 60033814 T2 DE60033814 T2 DE 60033814T2 DE 60033814 T DE60033814 T DE 60033814T DE 60033814 T DE60033814 T DE 60033814T DE 60033814 T2 DE60033814 T2 DE 60033814T2
Authority
DE
Germany
Prior art keywords
factor viii
monoclonal antibody
factor
human
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60033814T
Other languages
German (de)
English (en)
Other versions
DE60033814D1 (de
Inventor
Marc G. Jacquemin
Jean-Marie R. Saint-Remy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Desire Collen Research Foundation vzw
Original Assignee
Desire Collen Research Foundation vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9916450.1A external-priority patent/GB9916450D0/en
Application filed by Desire Collen Research Foundation vzw filed Critical Desire Collen Research Foundation vzw
Application granted granted Critical
Publication of DE60033814D1 publication Critical patent/DE60033814D1/de
Publication of DE60033814T2 publication Critical patent/DE60033814T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60033814T 1999-07-14 2000-07-13 Monoklonaler Antikörper der Faktor VIII selbst in molarem Überschuß nur teilweise inaktiviert und eine Methode zur Herstellung solch eines Antikörpers Expired - Lifetime DE60033814T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14389199P 1999-07-14 1999-07-14
US143891P 1999-07-14
GBGB9916450.1A GB9916450D0 (en) 1999-07-14 1999-07-14 Ligands for use in therapeutic compounds for the treatment of hemostasis disorders
GB9916450 1999-07-14
PCT/EP2000/006677 WO2001004269A1 (en) 1999-07-14 2000-07-13 Ligands for use in therapeutic compositions for the treatment of hemostasis disorders

Publications (2)

Publication Number Publication Date
DE60033814D1 DE60033814D1 (de) 2007-04-19
DE60033814T2 true DE60033814T2 (de) 2007-11-08

Family

ID=26315767

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60033814T Expired - Lifetime DE60033814T2 (de) 1999-07-14 2000-07-13 Monoklonaler Antikörper der Faktor VIII selbst in molarem Überschuß nur teilweise inaktiviert und eine Methode zur Herstellung solch eines Antikörpers

Country Status (11)

Country Link
EP (1) EP1194528B1 (enExample)
JP (2) JP4297207B2 (enExample)
AT (1) ATE356201T1 (enExample)
AU (1) AU781638B2 (enExample)
CA (1) CA2381125C (enExample)
CY (1) CY1107638T1 (enExample)
DE (1) DE60033814T2 (enExample)
DK (1) DK1194528T3 (enExample)
ES (1) ES2283308T3 (enExample)
PT (1) PT1194528E (enExample)
WO (1) WO2001004269A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829085B2 (en) 1999-07-14 2010-11-09 Life Sciences Research Partners Vzw Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII
ES2346189T3 (es) 2001-01-11 2010-10-13 Life Sciences Research Partners Vzw Metodo y composicion farmaceutica para prevenir y/o tratar el sindrome de respuesta inflamatoria generalizada.
DE60230037D1 (de) * 2001-06-12 2009-01-08 Chemo Sero Therapeut Res Inst Humanantikörper gegen blutgerinnungsfaktor viii
EP1388544A1 (en) 2002-07-31 2004-02-11 D. Collen Research Foundation vzw Anti-idiotypic antibodies against factor VIII inhibitor and uses thereof
JP4422430B2 (ja) 2003-05-14 2010-02-24 帝國製薬株式会社 エストロゲン及び／又はプロゲストゲン含有外用貼付剤
JP4934796B2 (ja) * 2003-08-14 2012-05-16 トロンボジェニクス・ナムローゼ・フエンノートシャップ 可変抗体
JP2008512097A (ja) 2004-09-07 2008-04-24 アーケミックス コーポレイション アプタマー医薬品化学
US7566701B2 (en) 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
CA2616902A1 (en) * 2005-07-29 2007-02-15 Life Sciences Research Partners Vzw Human inhibitory anti-factor viii antibodies binding to the a2 domain
FR2892724B1 (fr) 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
FR2897868B1 (fr) * 2006-02-24 2012-08-31 Lab Francais Du Fractionnement Anticorps anti-idiotypiques neutralisant l'activite inhibitrice d'un anticorps inhibiteur dirige contre le domaine c1 du facteur viii.
EP2451835A1 (en) 2009-07-10 2012-05-16 ThromboGenics N.V. Variants of plasminogen and plasmin
ES2534911T3 (es) 2009-08-28 2015-04-30 Thrombogenics N.V. Uso de plasmina para el tratamiento de fallo de filtración después de trabeculectomía
RU2604807C2 (ru) 2011-01-05 2016-12-10 ТромбоДженикс НВ Варианты плазминогена и плазмина
JP6000353B2 (ja) 2011-08-12 2016-09-28 スロンボジェニックス・ナムローゼ・フェンノートシャップＴｈｒｏｍｂｏＧｅｎｉｃｓ ＮＶ プラスミノーゲンおよびプラスミンの変異体
ES2628321T3 (es) 2011-12-01 2017-08-02 Thrombogenics N.V. Mejora del resultado de una trabeculectomía
KR101395736B1 (ko) * 2012-07-10 2014-05-16 아주대학교산학협력단 인간 혈액응고인자 ⅷ 도메인 특이적 항체 및 이의 제조방법
JP2019507746A (ja) 2016-03-10 2019-03-22 オクシュリオン エヌブイ 胎盤増殖因子のアンタゴナイズによる後眼部線維症の阻害
CA3062238A1 (en) * 2017-05-11 2018-11-15 Vib Vzw Glycosylation of variable immunoglobulin domains

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose

Also Published As

Publication number Publication date
WO2001004269A1 (en) 2001-01-18
AU781638B2 (en) 2005-06-02
JP2003504045A (ja) 2003-02-04
EP1194528A1 (en) 2002-04-10
CA2381125A1 (en) 2001-01-18
ES2283308T3 (es) 2007-11-01
JP4297207B2 (ja) 2009-07-15
AU6273000A (en) 2001-01-30
JP4297225B2 (ja) 2009-07-15
EP1194528B1 (en) 2007-03-07
PT1194528E (pt) 2007-05-31
CY1107638T1 (el) 2013-04-18
DE60033814D1 (de) 2007-04-19
CA2381125C (en) 2013-04-23
JP2008295455A (ja) 2008-12-11
ATE356201T1 (de) 2007-03-15
DK1194528T3 (da) 2007-07-09

Similar Documents

Publication Publication Date Title
DE69736197T2 (de) Antikoagulierende humanisierte Antikörper gegen Faktor IX, zur Verwendung in der Behandlung von Thrombose
JP4297225B2 (ja) 止血障害処置のための治療組成物に使用するためのリガンド
DE60035356T2 (de) Faktor ix/faktor ixa aktivierende antikörper
DE69132352T2 (de) Protein-antagonisten der blut-koagulation und ihre verwendung
EP2297207B1 (en) Use of anti-factor xi antibodies for prevention or treatment of thrombus formation
DE69006851T2 (de) Blutgerinnungshemmende zusammensetzungen aus faktor xa.
CN109153726A (zh) 抗因子xi的活性位点的单克隆抗体及其用途
DE60032029T2 (de) Antithrombose agenzien
DE69011531T2 (de) Von faktor vii abgeleitete peptide mit antihämostatischer wirkung.
DE69232669T2 (de) Mit gp11b/iiia reaktive humane antikörper
DE69621591T2 (de) Medikament welches Protein C aktivierendes Peptid enthält
US20030175268A1 (en) Method and pharmaceutical composition for preventing and/or treating systemic inflammatory response syndrome
US20020136725A1 (en) Antithrombotic agents
DE68919504T2 (de) Beschleunigung der Lyse von Gerinnsel.
US7067313B1 (en) Ligands for use in therapeutic compositions for the treatment of hemostasis disorders
EP1222929B1 (en) Method and pharmaceutical composition for preventing and/or treating systemic inflammatory response syndrome
DE60033234T2 (de) Zelllinien, liganden und antikörperfragmente zur verwendung in pharmazeutischen zusammensetzungen zur vorbeugung und behandlung von krankhaften veränderungen der homöostase
DE19820663A1 (de) Rekombinante Antikörper
HK1029513B (en) Anticoagulant humanised antibodies against factor ix, for use in the treatment of thrombosis
HK1109339A (en) Antithrombotic agents
HK1107932A (en) Anticoagulant agents useful in treatment of thrombosis

Legal Events

Date Code Title Description
8364 No opposition during term of opposition